Loading…
AURO-RAMIPRIL is a brand name for Ramipril, supplied as a capsule. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: AND CLINICAL USE ................................................................................. 3 CONTRAINDICATIONS ..................................................................................................... 4 WARNINGS AND…
Verbatim from this product's HC label. Tap a section to expand.
). Should the patient receiving AURO-RAMIPRIL experience any unexplained symptoms particularly during the first weeks or months of treatment, it is recommended that a full set of liver function tests and any other necessary investigations be carried out.
Discontinuation of AURO-RAMIPRIL should be considered when appropriate. There are no adequate studies in patients with cirrhosis and/or liver dysfunction. In patients with impaired liver function, response to the treatment with AURO-RAMIPRIL may be either increased or reduced.
In addition, in patients in whom severe liver cirrhosis with oedema and/or ascites is present, the RAS may be significantly activated. AURO-RAMIPRIL should be used with particular caution in patients with pre-existing liver abnormalities.
In such patients baseline liver function tests should be obtained before administration of the drug and close monitoring of response and metabolic effects should apply (see ACTION AND CLINICAL PHARMACOLOGY, Special Populations and conditions, Hepatic Insufficiency).
Rarely, ACE inhibitors, including AURO-RAMIPRIL, have been associated with a syndrome that starts with cholestatic jaundice and progresses to fulminant hepatic necrosis and (sometimes) death. The mechanism of this syndrome is not understood.
Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up. Immune Angioedema – Head, and Neck or Extremities Angioedema has been reported in patients with ACE inhibitors including ramipril.
Life threatening angioedema has been reported in patients with ACE inhibitors, including ramipril. 2%. Angioedema involving the face, extremities, lips, tongue, glottis and/or larynx has been reported in patients treated with ACE inhibitors.
Angioedema associated with laryngeal involvement may be fatal. If laryngeal stridor or angioedema of the face, extremities, lips, tongue, or glottis occurs, AURO-RAMIPRIL should be discontinued immediately, the patient treated appropriately in accordance with accepted medical care, and carefully observed until the swelling disappears.
In instances where swelling is confined to the face and lips, the condition generally resolves without treatment, although antihistamines may be useful in relieving symptoms. 5 mL of subcutaneous epinephrine solution 1:1000) should be administered promptly (see ADVERSE REACTIONS, Clinical Trial Adverse Drug Reactions, Essential Hypertension, Less Common Clinical Trial Adverse Drug Reactions (<1%), Body as a whole).
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Ramipril in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
An increased risk of angioedema is possible with concomitant use of other drugs which may cause angioedema. g. g. sitagliptin) or neutral endopeptidase (NEP) inhibitor may be at increased risk for angioedema. Caution should be used when initiating ACE inhibitor therapy in patients AURO-RAMIPRIL PRODUCT MONOGRAPH Page 9 of 44 already taking a mTOR, DPP-IV or NEP inhibitor or vice versa (see DRUG INTERACTIONS).
Concomitant use of sacubitril/valsartan A potential increased risk of angioedema has been reported with concomitant use of sacubitril/valsartan and ACE inhibitors. (see CONTRAINDICATIONS) Angioedema – Intestinal Intestinal angioedema has been reported in patients treated with ACE inhibitors.
These patients presented with abdominal pain (with or without nausea or vomiting); in some cases facial angioedema also occurred. The intestinal angioedema symptoms resolved after stopping the ACE inhibitor. The incidence of angioedema during ACE inhibitor therapy has been reported to be higher in black than in non-black patients.
Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased risk of angioedema while receiving an ACE inhibitor (see CONTRAINDICATIONS). Angioedema, including laryngeal edema, may occur especially following the 1st dose of AURO- RAMIPRIL.
g. polyacrylonitrile (PAN)] and treated concomitantly with an ACE inhibitor. Therefore, the use of AURO-RAMIPRIL in patients dialyzed with high-flux membranes is contraindicated (see CONTRAINDICATIONS). Dialysis should be stopped immediately if symptoms such as nausea, abdominal cramps, burning, angioedema, shortness of breath and severe hypotension occur.
Symptoms are not relieved by antihistamines. If such treatment is required, consideration should be given to using a different type of dialysis membrane or a different class of antihypertensive agents. Anaphylactoid reactions during LDL apheresis Rarely, patients receiving ACE inhibitors during low density lipoprotein apheresis with dextran sulfate have experienced life-threatening anaphylactoid reactions.
These reactions were avoided by temporarily withholding the ACE inhibitor therapy prior to each apheresis. Therefore, the use of AURO-RAMIPRIL in patients receiving low density lipoprotein apheresis with dextran sulfate is contraindicated (see CONTRAINDICATIONS).
If such treatment is required, consideration should be given to using a different type of apheresis or a different class of antihypertensive agents. g. bees, wasps) venoma. In the same patients, these reactions have been avoided when ACE inhibitors were temporarily withheld for ≥24 hours, but they have reappeared upon […]